Sperri lands $246,000 grant in NPC's $1M bioeconomy tranche
What's the deal? SperriDealroom has a profile for this one. Try Dealroom → secured a US$252.7K (roughly $246,000) grant from Natural Products Canada (NPC)Dealroom has a profile for this one. Try Dealroom →, part of a broader $1,016,330 investment the organisation announced across five early-stage Canadian companies in October.
What does the company do? Sperri works in plant-based nutrition and meal replacement, one strand of Canada's bio-based innovation pipeline. The other recipients — Novagevity, Catalera Biosolutions, ToothpodDealroom has a profile for this one. Try Dealroom →, Sustainable Bioproducts Innovations, and Naturfect Natural Solutions — span functional foods, agricultural biologicals, fat-replacement ingredients, and natural household care.
Why it matters: The grant sits around the middle of the pack by size, landing near the 52nd percentile among comparable deals. For an early-stage firm, that validation helps run trials and prepare products for shelves.
What's the endgame? NPC says its money will enable $2,543,328 in total project activities across three provinces. The firm has now invested over $15.2 million across more than 100 Canadian startups.
Why now? The tranche follows $1.52 million across nine startups in May 2026 and $804,000 across five in February, part of a recurring commercialisation program. In July, Ottawa announced $50 million for NPC to back both startup funding and scale-up processing capacity, with individual support potentially ranging from $150,000 to $5 million.
"Being in early with companies like these is where our support does the most work," said Shelley King, founder and chief executive officer of Natural Products Canada.
The signal: This latest round is modest against Ottawa's $50 million commitment, but it shows the funding pipeline remains active across food, agriculture, and consumer products. Its significance lies less in the dollar figures than in helping early-stage firms validate products and move toward commercialisation at home and abroad.
Read more: financialpost.com
Image credit: Generated with Gemini
